Table 6 Comparisons of trends in acquired non-susceptibility in Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae
Microbe | Type of non-susceptibility | Surveillance Area | Trends in proportions of non-susceptibility (Time period) | |
|---|---|---|---|---|
E. coli | Gentamicin non-susceptibility | Levanger Hospital | 0.5% (2002–05) | 3.3% (2010–13) |
Iceland | 2.9% (2010) | 4.1% (2013) | ||
Norway | 0.6% (2003) | 7.7% (2014) | ||
EU/EEA | 5.2% (2002) | 9.9% (2013) | ||
Bulgaria | 15.8% (2003) | 32.1% (2013) | ||
E. coli | Resistance to 3rd generation cephalosporins | Levanger Hospital | 0 (2002–05) | 1.7% (2010–13) |
Norway | 1.5% (2008) | 5.8% (2014) | ||
EU/EEA | 2.0% (2002) | 12.6% (2013) | ||
Bulgaria | 24.8% (2010) | 39.6% (2013) | ||
S. aureus | MRSA | Levanger Hospital | 0 (2002–05) | 1.0% (2010–13) |
Norway | 0.3% (2002) | 0.8% (2014) | ||
EU/EEA | 25.6% (2007) | 18.0% (2013) | ||
Malta | 52.0% (2007) | 51.8% (2013) | ||
Romania | 39.1% (2010) | 64.5% (2013) | ||
S. pneumoniae | PNSP | Levanger Hospital | 0 (2002–05) | 3.0% (2010–13) |
Netherlands | 2.0% (2010) | 1.1% (2013) | ||
Norway | 0.9% (2002) | 5.5% (2014) | ||
Cyprus | 41.7% (2010) | 40.0% (2013) | ||